[ad_1]
He said that if approved, he would try to administer the medication to as many people as possible.
“We are moving very fast with the FDA,” Daniel O’Neill said in an interview with NBC’s Today. “And I think they will respond very quickly,” he added.
According to the preliminary results of a large clinical study carried out in the USA. USA, In collaboration with Gilead and the Institutes of Health (NIH), remdeshivir accelerates the recovery time of patients with Covid-19 by 31%. Patients receiving remdeshivir he recovered in 11 days, on average, instead of the 15 days it took for those who received pseudo-medication.
Recovery is defined as leaving the hospital or returning to normal activities. The statistical reliability of this result is high.
The trial involved 1,063 patients in 47 areas of the United States and another 21 in Europe and Asia.. To date, this is the largest study on remedisvir, the results of which are available.
In terms of mortality, the result is not significant, that is, the small difference between the two groups may be random. In the group that received remedisviri, the mortality rate was 8%, compared to 11% in the group that received the pseudo drug, suggesting that the drug improves survival.
Dimopoulos for Remdesivir: For the first time we have an antiviral drug that shows results
“For the first time we have an antiviral drug that shows results in this disease” EKPA President Mr. Dimopoulos noted in the SKAI newsletter.
The EKPA president explained that there are studies in progress and that we will have short results.
However, he noted that Remdesivir, not the cure for the disease. “The treatment of the disease is multifactorial because it is a multisystemic disease. It involves many systems.”
However, as he stressed, “It is encouraging that we have a study showing benefit in the treatment of the disease “.
See all the latest News from Greece and the world, the moment they occur, in Newsbomb.gr.
[ad_2]
